NCT05007470View on ClinicalTrials.gov

Alcoholic Liver Disease and the Gut Microbiome

NAActive, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 31, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

September 1, 2025

Conditions
Alcohol Use DisorderAlcoholic Liver DiseaseMicrobiome
Interventions
DRUG

VSL #3 112.5 Capsule

VSL#3 is a commercial probiotic mixture consisting of eight bacterial strains: Four strains of Lactobacillus (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus delbrueckii subspecies bulgaricus), three strains of Bifidobacterium (Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), and one strain of Streptococcus (Streptococcus salivarius subspecies thermophilus).

OTHER

Placebo

100 mg sugar

Trial Locations (1)

90095

University of California, Los Angeles, Los Angeles

All Listed Sponsors
lead

University of California, Los Angeles

OTHER